Talis Biomedical Corp financial data

Location
Chicago, IL
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 19 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 866 % -23.2%
Debt-to-equity 39.5 % +43%
Return On Equity -79.73 % -12.8%
Return On Assets -57.16 % -3.2%
Operating Margin -13,510 % -3.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,686,494 shares +7.3%
Common Stock, Shares, Outstanding 1,822,153 shares +0.17%
Entity Public Float 8,151,667,000 USD +11%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1,822,422 shares +0.28%
Weighted Average Number of Shares Outstanding, Diluted 1,822,422 shares +0.28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 408,000 USD -85.7%
Research and Development Expense 20,477,000 USD -64.1%
Costs and Expenses 55,530,000 USD -40.4%
Operating Income (Loss) -55,122,000 USD +38.9%
Net Income (Loss) Attributable to Parent -51,026,000 USD +40.5%
Earnings Per Share, Basic -28 USD/shares +56.6%
Earnings Per Share, Diluted -28 USD/shares +56.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59,867,000 USD -39%
Assets, Current 63,601,000 USD -37.6%
Property, Plant and Equipment, Net 425,000 USD -88%
Operating Lease, Right-of-Use Asset 7,907,000 USD -50.7%
Other Assets, Noncurrent 766,000 USD -50.3%
Assets 72,699,000 USD -40.9%
Accounts Payable, Current 3,790,000 USD +52.1%
Accrued Liabilities, Current 634,000 USD -32.4%
Liabilities, Current 8,196,000 USD -11.5%
Operating Lease, Liability, Noncurrent 15,877,000 USD -10%
Liabilities 24,073,000 USD -10.5%
Retained Earnings (Accumulated Deficit) -561,845,000 USD -10%
Stockholders' Equity Attributable to Parent 48,626,000 USD -49.4%
Liabilities and Equity 72,699,000 USD -40.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6,427,000 USD +61%
Net Cash Provided by (Used in) Financing Activities 2,000 USD -93.9%
Net Cash Provided by (Used in) Investing Activities 30,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,822,153 shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6,395,000 USD +61.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60,633,000 USD -39.8%
Deferred Tax Assets, Valuation Allowance 160,784,000 USD +14.5%
Deferred Tax Assets, Gross 164,450,000 USD +11.2%
Operating Lease, Liability 18,800,000 USD -7.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 23,437,000 USD -10.8%
Property, Plant and Equipment, Gross 15,974,000 USD +5.4%
Operating Lease, Liability, Current 2,923,000 USD +6.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3,144,000 USD +5.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 3,055,000 USD +1.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4,637,000 USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3,235,000 USD +5.9%
Deferred Tax Assets, Operating Loss Carryforwards 81,749,000 USD +22.5%
Unrecognized Tax Benefits 10,338,000 USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3,329,000 USD +5.9%
Deferred Tax Assets, Net of Valuation Allowance 3,666,000 USD -50.9%
Share-based Payment Arrangement, Expense 3,484,000 USD -28%